Publications by authors named "B Calimlim"
In atopic dermatitis (AD), the real-world impact of achieving itch and skin lesion treatment targets compared to partial improvement remains unclear. We assessed the relationship between itch relief (reduction in Worst Itch Numeric Rating Scale [WI-NRS]) and skin clearance (Investigator Global Assessment [IGA] 0/1) with other patient-reported outcomes. Using TARGET-DERM AD registry data on adults receiving standard-of-care treatment, we described and modeled the relationship of itch severity (Worst Itch Numeric Rating Scale [WI-NRS]) and skin lesion severity (IGA) outcomes with patient-reported (quality of life ([DLQI)], AD severity [(POEM]), sleep ([Sleep-NRS]), and skin pain [(Pain-NRS]).
View Article and Find Full Text PDFArticle Synopsis
- Upadacitinib shows faster and more effective results in reducing atopic dermatitis severity compared to dupilumab over 24 weeks, based on the Eczema Area and Severity Index (EASI).
- In a study, patients treated with upadacitinib achieved greater skin clearance rates of ≥75%, ≥90%, and 100% in all analyzed body regions earlier than those on dupilumab.
- Patient feedback indicated that those on upadacitinib reported significantly better outcomes for symptoms in the head and neck area as soon as week 1.
Article Synopsis
- The Measure Up 1, 2, and AD Up studies assessed the effectiveness and side effects of upadacitinib for treating atopic dermatitis in adolescents aged 12-17 over a period of 76 weeks, extending the research beyond the previously available 52-week data.
- In a randomized clinical trial, participants received either upadacitinib (15 mg or 30 mg) or a placebo, with some receiving topical corticosteroids, allowing for varied analysis of its efficacy and safety.
- Results showed that a significant percentage of adolescents achieved a major improvement in their condition, with 89.1%, 84.4%, and 87.8% meeting the criteria for reduction in severity, showcasing the medication
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).
Jonathan I Silverberg Christopher G Bunick H Chih-Ho Hong Pedro Mendes-Bastos Linda Stein Gold Brian Calimlim
Br J Dermatol
December 2024
Article Synopsis
- * The study compared the effectiveness and safety of upadacitinib (UPA) and dupilumab (DUPI) in adolescents and adults with moderate-to-severe AD over 16 weeks, with UPA showing better results in reducing skin severity and itching.
- * UPA was found to be significantly more effective than DUPI in achieving the treatment goals, with no new safety concerns reported during the study.
Article Synopsis
- - The study focused on atopic dermatitis (AD) and evaluated how much time patients spent with clear skin and minimal itch while being treated with upadacitinib compared to a placebo and dupilumab.
- - Researchers analyzed data from three phase 3 studies involving nearly 2,400 patients, with treatments lasting from 16 to 24 weeks and assessed using established skin severity and itch scales.
- - Results showed that patients on upadacitinib experienced significantly more days with better skin conditions and reduced itching compared to those on placebo or dupilumab.